Top Markets
Coin of the day
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
株式のランク #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
株価
$0.12164306
最終同期: 2024-11-11
時価総額
$38.53M
変化(1日)
-4.14%
変化(1年)
0.00%
AU
取引 PharmAust Limited (PAA)

カテゴリー

PharmAust Limited(PAA)のP/B比率
August 2026 時点のP/B比率 TTM: 8.34
PharmAust Limited の最新の財務報告および株価によると、現在のP/B比率(TTM)は 8.34 です。2024 年末時点でのP/B比率は 7.07 でした。
PharmAust Limited の P/B 比率の履歴(2001 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) 8.34 -66.96%
2025 25.24 257.09%
2024 7.07 14.20%
2023 6.19 118.92%
2022 2.83 -12.60%
2021 3.24 -39.88%
2020 5.38 357.35%
2019 1.18 54.04%
2018 0.76 -23.38%
2017 1.00 -25.35%
2016 1.34 27.23%
2015 1.05 -36.35%
2014 1.65 -90.55%
2013 17.45 671.52%
2012 2.26 -68.36%
2011 7.15 99.09%
2010 3.59 333.85%
2009 0.83 5.81%
2008 0.78 -13.33%
2007 0.90 -33.57%
2006 1.36 -44.16%
2005 2.43 -64.38%
2004 6.83 667.26%
2003 0.89 -50.23%
2002 1.79 19.65%
2001 1.49 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.3419 -23.94%
US
6.2413 -25.15%
NL
2.5054 -69.95%
AU
3.7087 -55.52%
US
- -
CH